VYNE Therapeutics Inc. · NASDAQ:VYNE

VYNE Therapeutics — Technical Presentation (November 2021)

9 slides from VYNE Therapeutics's technical presentation, Nov 10, 2021

  1. Slide 1: Topical BET Inhibitor (VYN201) Preclinical Study Update

    Topical BET Inhibitor (VYN201) Preclinical Study Update November 10, 2021

  2. Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to statements regarding the development of VYNE’s product candidates and other statements regarding the future expec

  3. Slide 3: VYN201: Comparable Efficacy to Superpotent Steroid Clobetasol in a TH17-Mediated Murine Model

    VYN201: Comparable Efficacy to Superpotent Steroid Clobetasol in a TH17- Mediated Murine Inflammation Model; Potential for Greater Tolerability Dorsal depilated BALB-C mice were dosed topically for 14 days with 100mg topical IMI cream (Day 1-7: induction phase, Day 8- 14: treatment phase). N=4 anima

  4. Slide 4: Dose-Dependent Reduction in Pro-Inflammatory Biomarkers in TH17-Mediated Murine Model

    VYN201: Dose-Dependent Reduction in Pro-Inflammatory Biomarkers in TH17-Mediated Murine Inflammation Model Indicates Target Engagement Dorsal depilated BALB-C mice were dosed topically for 14 days with 100mg topical IMI cream (Day 1-7: induction phase, Day 8-14: treatment phase). N=4 animals were as

  5. Slide 5: Normal Skin Physiology in TH17-Mediated Murine Inflammation Model Suggests VYN201 Well Tolerated

    VYN201: Normal Skin Physiology in TH17-Mediated Murine Inflammation Model Suggests VYN201 Well Tolerated (Day 7) VYN201 Vehicle VYN201 0.1% Clobetasol Cream 0.05% • No appreciable improvement in • Substantial resolution of clinical signs • Substantial resolution of clinical signs clinical signs • Sk

  6. Slide 6: VYN201 Significantly Reduced Expression of Several Key Pro-Inflammatory Proteins in Human Tissue

    VYN201 Significantly Reduced Expression of Several Key Pro-Inflammatory Proteins Relevant to Th17-mediated Autoimmune Diseases in Human Tissue1 120 -99.5% 100 >95% Inhibition seen with assays for IL-36γ & LP-10 Percent inhibition (IL-17α) 80 Interleukin 36-gamma 60 IL36γ is implicated in upregulatin

  7. Slide 7: Demonstrated Anti-Fibrotic Activity without Delay in Healing Time in Murine Skin Healing Model

    VYN201: Demonstrated Anti-Fibrotic Activity without Delay in Healing Time in Murine Skin Healing Model Female hairless mice (n=4/group) had two identical 10mm incisions made either side of the flank. Animals were topically dosed 1X daily with 100mg VYN201 vehicle, VYN201 1% or a hydroalcoholic gel*

  8. Slide 8: Little Evidence of Residual Swelling and Macular Wound Appearance in Murine Skin Healing Model

    VYN201: Little Evidence of Residual Swelling and Macular Wound Appearance in Murine Skin Healing Model VYN201 Vehicle VYN201 1% Hydroalcoholic gel • Still evidence of minor swelling • Little evidence of residual swelling • Moderate swelling clearly evident at around incision sites • Wound appears mo

  9. Slide 9: Summary of Preclinical Studies

    Confidential – For Internal Use Only. Summary of Preclinical Studies • VYN201 significantly reduced the expression of several key pro-inflammatory cytokines relevant to Th17-mediated autoimmune diseases • VYN201 demonstrated improvement in reducing fibrotic tissue mass and overall skin repair outcom

VYNE Therapeutics — Technical Presentation (November 2021) on 6ix